Biotech News
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data from first-in-human trial were shared in oral presentation at AASLD The Liver Meeting ® and simultaneously published in The New England Journal of
